Citations

Clear

4847 citation(s) found for "Tu, Eric".

O3‐03‐08: Biomarker predictors of cognitive decline in healthy older participants in the Alzheimer's Disease Neuroimaging Initiative
Landau, Susan , Reiman, Eric M. , Foster, Norman L. , Aisen, Paul , Trojanowski, John Q. , Shaw, Leslie M. , Petersen, Ronald C. , Weiner, Michael W. , Jagust, William J. , Harvey, Danielle , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | July 11, 2010 | Volume: 6 | Issue: 4S_Part_4 | Pages: No page available

10.1016/j.jalz.2010.05.411 Get It

O3‐02‐05: Cognitive correlates of frontotemporal amyloid deposition in presymptomatic APOE e4 carriers
Caselli, Richard J. , Hoffman‐Snyder, Charlene , Findley, Scott, Woodruff, Bryan K. , Reiman, Eric M. , Dueck, Amylou C. , Locke, Dona E.C.

Mayo Clinic

Alzheimer's & Dementia | July 11, 2010 | Volume: 6 | Issue: 4S_Part_4 | Pages: No page available

10.1016/j.jalz.2010.05.401 Get It

IC‐P‐145: Effect of APOE4 Status and Alzheimer's Disease on Posterior Cingulate Connectivity
Avula, Ramesh, Przybelski, Scott A. , Younkin, Steven G. , Gunter, Jeff, Petersen, Ronald C. , Machulda, Mary M. , Jones, David T. , McDade, Eric , Vemuri, Prashanthi , Senjem, Matthew L. , Boeve, Bradley F. , Knopman, David S. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | July 11, 2010 | Volume: 6 | Issue: 4S_Part_2 | Pages: No page available

10.1016/j.jalz.2010.05.160 Get It

P2‐380: Effect of APOE4 status and Alzheimer's disease on posterior cingulate connectivity
Avula, Ramesh, Przybelski, Scott A. , Younkin, Steven G., Gunter, Jeff, Petersen, Ronald C. , Machulda, Mary M. , Jones, David T. , McDade, Eric , Vemuri, Prashanthi , Senjem, Matthew L. , Boeve, Bradley F. , Knopman, David S. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | July 11, 2010 | Volume: 6 | Issue: 4S_Part_14 | Pages: No page available

10.1016/j.jalz.2010.05.1432 Get It

P1‐096: TOMM40, APOE, and age of onset of Alzheimer's disease
Caselli, Richard J. , Saunders, Ann M. , Huentelman, Matthew J. , Reiman, Eric M. , Roses, Allen D., Lutz, Michael W.

Mayo Clinic

Alzheimer's & Dementia | July 11, 2010 | Volume: 6 | Issue: 4S_Part_7 | Pages: No page available

10.1016/j.jalz.2010.05.644 Get It

IC‐P‐062: Cognitive Performance Correlates with Resting State Connectivity and is Effected by APOE Status
Younkin, Steve, Petersen, Ronald C. , Jones, David T. , Machulda, Mary M. , McDade, Eric , Vemuri, Prashanthi , Zeng, Guang‐Zhi , Knopman, David S. , Boeve, Bradley F. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | July 11, 2010 | Volume: 6 | Issue: 4S_Part_1 | Pages: No page available

10.1016/j.jalz.2010.05.077 Get It

Comparing predictors of conversion and decline in mild cognitive impairment
Landau, Susan , Harvey, Danielle , Madison, Catherine, Reiman, Eric M. , Foster, Norman L. , Aisen, Paul , Petersen, Ronald C. , Shaw, Leslie M. , Trojanowski, John Q. , Weiner, Michael W. , Jagust, William J. , Jack, Clifford R. , Harvey, Danielle J

Mayo Clinic

Neurology | June 30, 2010 | Volume: 75 | Issue: 3 | Pages: 230-238

10.1212/wnl.0b013e3181e8e8b8 | PMID 20592257 Get It

Evaluation of Oligonucleotide Sequence Capture Arrays and Comparison of Next-Generation Sequencing Platforms for Use in Molecular Diagnostics
Hoppman‐Chaney, Nicole L., Peterson, Lisa M., Klee, Eric W. , Middha, Sumit , Courteau, Laura K., Ferber, Matthew J.

Mayo Clinic

Clinical Chemistry | June 20, 2010 | Volume: 56 | Issue: 8 | Pages: 1297-1306

10.1373/clinchem.2010.145441 | PMID 20562348 Get It

BACKGROUND Next-generation DNA sequencing (NGS) techniques have the potential to revolutionize molecular diagnostics; however, a thorough evaluation of these technologies is necessary to ensure their performance meets or exceeds that of current clinical sequencing methods. METHODS We evaluated the NimbleGen Sequence Capture 385K Human Custom Arrays for enrichment of 22 genes. We sequenced each sample on both the Roche 454 Genome Sequencer FLX (GS-FLX) and the Illumina Genome Analyzer II (GAII) to compare platform performance. RESULTS Although the sequence capture method allowed us to rapidly develop a large number of sequencing assays, we encountered difficulty enriching G+C–rich regions. Although a high proportion of reads consistently mapped outside of the targeted regions, >80% of targeted bases for the GAII and >30% of bases for the GS-FLX were covered by a read depth of ≥20, and >90% of bases for the GAII and >80% of bases for the GS-FLX were covered by a read depth of ≥5. We observed discrepancies among sequence variants identified by the different platforms. CONCLUSIONS Although oligonucleotide arrays are quick and easy to develop, some problematic regions may evade capture, necessitating sequential redesigning for complete optimization. Neither sequencing technology was able to detect every variant identified by Sanger sequencing because of well-known drawbacks of the NGS technologies. The rapidly decreasing error rates and costs of these technologies, however, coupled with advancing bioinformatic capabilities, make them an attractive option for molecular diagnostics in the very near future.
Endothelial-derived tissue factor pathway inhibitor regulates arterial thrombosis but is not required for development or hemostasis
White, Thomas A. , Johnson, Tucker F. , Zarzhevsky, Natalia, Tom, Cindy W., Delacroix, Sinny , Holroyd, Eric, Maroney, Susan A. , Singh, Ripudamanjit, Pan, Shuchong, Fay, William P. , Deursen, Jan van, Mast, Alan E. , Sandhu, Gurpreet S. , Simari, Robert D.

Mayo Clinic

Blood | June 2, 2010 | Volume: 116 | Issue: 10 | Pages: 1787-1794

10.1182/blood-2009-10-250910 | PMID 20516367 Get It

AbstractThe antithrombotic surface of endothelium is regulated in a coordinated manner. Tissue factor pathway inhibitor (TFPI) localized at the endothelial cell surface regulates the production of FXa by inhibiting the TF/VIIa complex. Systemic homozygotic deletion of the first Kunitz (K1) domain of TFPI results in intrauterine lethality in mice. Here we define the cellular sources of TFPI and their role in development, hemostasis, and thrombosis using TFPI conditional knockout mice. We used a Cre-lox strategy and generated mice with a floxed exon 4 (TFPIFlox) which encodes for the TFPI-K1 domain. Mice bred into Tie2-Cre and LysM-Cre lines to delete TFPI-K1 in endothelial (TFPITie2) and myelomonocytic (TFPILysM) cells resulted in viable and fertile offspring. Plasma TFPI activity was reduced in the TFPITie2 (71% ± 0.9%, P < .001) and TFPILysM (19% ± 0.6%, P < .001) compared with TFPIFlox littermate controls. Tail and cuticle bleeding were unaffected. However, TFPITie2 mice but not TFPILysM mice had increased ferric chloride–induced arterial thrombosis. Taken together, the data reveal distinct roles for endothelial- and myelomonocytic-derived TFPI.
Analysis of Complex Biomarkers for Human Immune-Mediated Disorders Based on Cytokine Responsiveness of Peripheral Blood Cells
Davis, John M. , Knutson, Keith L. , Strausbauch, Michael, Crowson, Cynthia S. , Therneau, Terry M. , Wettstein, Peter J., Matteson, Eric L. , Gabriel, Sherine E., Knutson, Keith L. , Davis, John M

Mayo Clinic

The Journal of Immunology | May 21, 2010 | Volume: 184 | Issue: 12 | Pages: 7297-7304

10.4049/jimmunol.0904180 | PMID 20495063 Get It

Abstract The advent of improved biomarkers promises to enhance the clinical care for patients with rheumatoid arthritis (RA) and other immune-mediated disorders. We have developed an innovative approach to broadly assess the cytokine responsiveness of human PBMCs using a multistimulant panel and multiplexed immunoassays. The objective of this study was to demonstrate this concept by determining whether cytokine profiles could discriminate RA patients according to disease stage (early versus late) or severity. A 10-cytokine profile, consisting of IL-12, CCL4, TNF-α, IL-4, and IL-10 release in response to stimulation with anti-CD3/anti-CD28, CXCL8 and IL-6 in response to CMV and EBV lysate, and IL-17A, GM-CSF, and CCL2 in response to human heat shock protein 60, easily discriminated the early RA group from controls. These data were used to create an immune response score, which performed well in distinguishing the early RA patients from controls and also correlated with several markers of disease severity among the patients with late RA. In contrast, the same 10-cytokine profile assessed in serum was far less effective in discriminating the groups. Thus, our approach lays the foundation for the development of immunologic “signatures” that could be useful in predicting disease course and monitoring the outcomes of therapy among patients with immune-mediated diseases.